Bill Meury, Karuna Therapeutics CEO
March 21, 2023 07:07 AM EDTUpdated 07:45 AM
Financing

Karuna to raise $400M in mar­ket a day af­ter pos­i­tive read­out of schiz­o­phre­nia drug

Katherine Lewin

News Reporter

Karuna Ther­a­peu­tics plans to raise $400 mil­lion in a stock sale, a day af­ter re­leas­ing more pos­i­tive da­ta for one of its schiz­o­phre­nia drugs, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times